Mourad Fadi H, Hoffbrand A Victor, Sheikh-Taha Marwan, Koussa Susane, Khoriaty Adlette I, Taher Ali
Department of Internal Medicine, The American University of Beirut Medical Centre, Beirut, Lebanon.
Br J Haematol. 2003 Apr;121(1):187-9. doi: 10.1046/j.1365-2141.2003.04240.x.
Desferrioxamine (DFX) alone (40-50 mg/kg/d s.c. over 8-12 h, five times weekly) was compared with combined DFX twice weekly and deferiprone (75 mg/kg/d) over 12 months in previously poorly chelated thalassaemia patients. Serum ferritin fell from 5506 +/- 635 microg/l (mean +/- SEM) to 3998 +/- 604 microg/l (P < 0.001; n = 14) in the DFX group and from 4153 +/- 517 microg/l to 2805 +/- 327 microg/l in the combined group (P < 0.01; n = 11). Deferiprone plus DFX produced a greater mean urine iron excretion (1.01 mg/kg/24 h) than iron intake from blood transfusion in each patient. Main side-effects were skin reactions (DFX alone), nausea and arthralgia (combined therapy). As chelation therapy, the combined protocol was as effective as DFX five times weekly.
在先前螯合治疗效果不佳的地中海贫血患者中，将去铁胺（DFX）单独使用（40 - 50 mg/kg/d，皮下注射，8 - 12小时内完成，每周5次）与去铁胺每周2次联合去铁酮（75 mg/kg/d）使用12个月的效果进行了比较。去铁胺组血清铁蛋白从5506±635μg/l（均值±标准误）降至3998±604μg/l（P<0.001；n = 14），联合治疗组从4153±517μg/l降至2805±327μg/l（P<0.01；n = 11）。去铁酮加去铁胺使每位患者的平均尿铁排泄量（1.01 mg/kg/24小时）高于输血铁摄入量。主要副作用为皮肤反应（仅使用去铁胺）、恶心和关节痛（联合治疗）。作为螯合疗法，联合方案与每周5次使用去铁胺的效果相同。
